Compare ASR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASR | NUVL |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | Mexico | United States |
| Employees | 1936 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 7.8B |
| IPO Year | N/A | 2021 |
| Metric | ASR | NUVL |
|---|---|---|
| Price | $336.36 | $102.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | ★ $365.00 | $134.13 |
| AVG Volume (30 Days) | 65.3K | ★ 547.2K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $8.74 | $1,235.73 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $249.21 | $55.54 |
| 52 Week High | $381.52 | $113.02 |
| Indicator | ASR | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 53.06 |
| Support Level | $317.21 | $101.37 |
| Resistance Level | $348.98 | $107.13 |
| Average True Range (ATR) | 10.17 | 3.63 |
| MACD | 2.19 | 0.87 |
| Stochastic Oscillator | 50.22 | 61.35 |
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The group's operating segments are Cancun, which generates maximum revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.